Tumor Infiltrating Lymphocytes is named as a drug or biological intervention in 6 clinical trials in our China trial register, 6 of which are recruiting. Lead sponsors include Essen Biotech (5) and Shanghai Juncell Therapeutics (1). Registered phases: Phase 1/2 and Phase EARLY_PHASE1. Conditions studied include Colorectal Cancer; Colon Cancer; Rectum Cancer.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05087745 | A Clinical Study on TIL for the Treatment of Advanced Solid Tumors (ClinicalTrials.gov ↗) Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects |
Phase EARLY_PHASE1 | Recruiting |
| NCT06530303 | Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer (ClinicalTrials.gov ↗) Colorectal Cancer, Colon Cancer, Rectum Cancer |
Phase 1/2 | Recruiting |
| NCT06532799 | TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer (ClinicalTrials.gov ↗) Stomach Cancer, Stomach Cancer Recurrent, Stomach Cancer, Adenocarcinoma |
Phase 1/2 | Recruiting |
| NCT06532812 | TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer (ClinicalTrials.gov ↗) Breast Cancer, Breast Carcinoma, Breast Cancer Metastatic |
Phase 1/2 | Recruiting |
| NCT06538012 | TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer (ClinicalTrials.gov ↗) Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell |
Phase 1/2 | Recruiting |
| NCT06640582 | TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas (ClinicalTrials.gov ↗) Brain Tumor, Brain Metastases, Brain Cancer |
Phase 1/2 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Colorectal Cancer | 1 |
| Colon Cancer | 1 |
| Rectum Cancer | 1 |
| Stomach Cancer | 1 |
| Stomach Cancer Recurrent | 1 |
| Stomach Cancer, Adenocarcinoma | 1 |
| Esophageal Cancer | 1 |
| Brain Tumor | 1 |
| Brain Metastases | 1 |
| Brain Cancer | 1 |
| Glioma | 1 |
| Advanced Solid Tumor | 1 |
| Tumor Infiltrating Lymphocytes | 1 |
| Treatment Side Effects | 1 |
| Effects of Immunotherapy | 1 |
| Lung Cancer | 1 |
| Lung Cancer Metastatic | 1 |
| Lung Cancer, Non-small Cell | 1 |
| Lung Cancer Recurrent | 1 |
| Breast Cancer | 1 |
| Breast Carcinoma | 1 |
| Breast Cancer Metastatic | 1 |
| Breast Cancer Triple Negative | 1 |
| Lead sponsor | Trials |
|---|---|
| Essen Biotech | 5 |
| Shanghai Juncell Therapeutics | 1 |
| Register | Tumor Infiltrating Lymphocytes trials |
|---|---|
| Clinical trials in China | 6 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tumor Infiltrating Lymphocytes works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tumor Infiltrating Lymphocytes (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.